Medication provision for patients who have experienced vascular catastrophes over the course of two years has reduced mortality in this group by nearly 20%. This was announced by Minister of Health Mikhail Murashko at the All-Russian Congress “Russia Thrombosis Day 2025.”
“Medication therapy for patients who have had vascular catastrophes and suffer from chronic heart failure, provided for a period of two years has resulted in a nearly 20% reduction in mortality in this category. This is a great achievement,” he emphasized. The head of the Ministry of Health noted that the coverage of drug therapy for patients reached 98%, and the implementation of centralized procurement of medications increased the efficiency of resource use by an additional 15%.
Murashko also highlighted the importance of stable drug supply and the development of domestic pharmaceutical production. “The pandemic taught us all that we need to rely on ourselves. When all countries want the same drugs and medical products, shortages occur.
This is unacceptable for our country. Therefore, we have available domestic medicines — anticoagulants, antiplatelet agents, and thrombolytics, across almost all groups. There are a total of 234 domestically produced drugs on the market,” the minister said. According to him, the range of available medications continues to expand, in particular, drugs for the treatment of hereditary dyslipidemia are being developed.
Murashko stated that Russia has also met its needs for diabetes medications. “We have domestically developed drugs for practically all types of therapy for blood sugar control. Almost any medication for the treatment of patients with diabetes, both type 1 and type 2, is fully accessible to the market and healthcare providers,” he reported.